Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Sorio

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Gynecologic Oncology|March 30, 2021
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study databaseFrancesca Falcone, Enrico Breda, Gabriella Ferrandina, et al.
Gynecologic Oncology|November 13, 2019
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancerSara Gagno, Elena Poletto, Michele Bartoletti, et al.
Gynecologic Oncology|November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialRoberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 1, 2020
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulvaMichele Bartoletti, Roberta Mazzeo, Marco De Scordilli, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2013
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisAndrea Vecchione, Barbara Belletti, Francesca Lovat, et al.
BMC Cancer|August 3, 2006
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialSandro Pignata, Giovanni Scambia, Antonella Savarese, et al.
BMC Cancer|September 3, 2008
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Critical Reviews in Oncology/Hematology|January 31, 2009
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Oncology|September 20, 2007
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective StudySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Clinical Pharmacology and Therapeutics|May 27, 2023
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and BevacizumabMaurizio Polano, Luca Bedon, Michele Dal Bo, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Gynecologic Oncology|March 30, 2021
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study databaseFrancesca Falcone, Enrico Breda, Gabriella Ferrandina, et al.
Gynecologic Oncology|November 13, 2019
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancerSara Gagno, Elena Poletto, Michele Bartoletti, et al.
Gynecologic Oncology|November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialRoberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 1, 2020
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulvaMichele Bartoletti, Roberta Mazzeo, Marco De Scordilli, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2013
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisAndrea Vecchione, Barbara Belletti, Francesca Lovat, et al.
BMC Cancer|August 3, 2006
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialSandro Pignata, Giovanni Scambia, Antonella Savarese, et al.
BMC Cancer|September 3, 2008
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Critical Reviews in Oncology/Hematology|January 31, 2009
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective studySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Oncology|September 20, 2007
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective StudySandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Clinical Pharmacology and Therapeutics|May 27, 2023
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and BevacizumabMaurizio Polano, Luca Bedon, Michele Dal Bo, et al.
Pageof 6